Vaxcyte, Inc. (PCVX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Vaxcyte, Inc. (PCVX) Healthcare & Pipeline Overview

Vaxcyte, Inc. is a clinical-stage biotechnology company specializing in novel protein vaccines, with a primary focus on combating bacterial infectious diseases. Their lead candidate, VAX-24, a 24-valent pneumococcal conjugate vaccine, is currently in Phase 1/2 clinical trials, positioning the company to address the significant unmet needs in preventing pneumococcal diseases.

What Is the Investment Thesis for PCVX?

Vaxcyte's investment thesis centers on its innovative vaccine technology and its potential to address significant unmet needs in the prevention of bacterial infectious diseases. The lead candidate, VAX-24, shows promise in providing broader coverage against pneumococcal disease compared to existing vaccines. Positive Phase 1/2 clinical trial data could serve as a major catalyst, driving investor confidence and potentially leading to partnerships or acquisitions. The company's pipeline, including VAX-XP, VAX-A1, and VAX-PG, offers further growth opportunities by targeting additional infectious diseases. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from established players in the vaccine market. With a market cap of $8.48B and a beta of 1.39, Vaxcyte presents a high-growth, high-risk investment profile.

Based on FMP financials and quantitative analysis

PCVX Key Highlights

Vaxcyte's lead vaccine candidate, VAX-24, is in Phase 1/2 clinical trials, targeting invasive pneumococcal disease and pneumonia.

• The company is developing VAX-XP to protect against emerging strains and address antibiotic resistance, showcasing their commitment to innovation.
• Vaxcyte's pipeline includes VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep, expanding their therapeutic focus.
• VAX-PG, a novel protein vaccine candidate, targets the keystone pathogen responsible for periodontitis, demonstrating their diverse approach to vaccine development.
• Vaxcyte changed its name from SutroVax, Inc. in May 2020, reflecting its evolution and strategic focus on vaccine development.

Who Are PCVX's Competitors?

PCVX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PCVX's Key Strengths?

Innovative vaccine technology platform.

• Strong pipeline of vaccine candidates.
• Experienced management team.
• Focus on addressing unmet needs in infectious disease prevention.

What Are PCVX's Weaknesses?

Clinical-stage company with no currently marketed products.

• Reliance on successful clinical trial outcomes.
• High research and development costs.
• Dependence on regulatory approvals.

What Could Drive PCVX Stock Higher?

Announcement of Phase 1/2 clinical trial results for VAX-24.

• Initiation of clinical trials for VAX-XP.
• Continued progress in the development of VAX-A1 and VAX-PG.
• Potential for strategic partnerships or collaborations.

What Are the Key Risks for PCVX?

Negative return on equity (-32.5%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
• Unfavorable clinical trial results for VAX-24 or other vaccine candidates.
• Regulatory delays or rejection of vaccine approvals.
• Competition from established vaccine manufacturers.
• High research and development costs.
• Intellectual property challenges.

What Are the Growth Opportunities for PCVX?

• Expansion of VAX-24: Vaxcyte has the opportunity to expand the use of VAX-24 beyond its current Phase 1/2 clinical trials. Positive results could lead to further clinical development and eventual commercialization, addressing a significant portion of the pneumococcal vaccine market.
• Development of VAX-XP: VAX-XP, designed to protect against emerging pneumococcal strains and address antibiotic resistance, represents a significant growth opportunity. As antibiotic resistance becomes an increasingly pressing global health concern, vaccines that can circumvent this issue will be highly valuable. Successful development and commercialization of VAX-XP could position Vaxcyte as a leader in addressing this critical need.
• Advancement of VAX-A1: The development of VAX-A1, a conjugate vaccine candidate targeting Group A Strep, offers another avenue for growth. Group A Strep infections are common and can lead to serious complications, creating a substantial market for an effective vaccine. Vaxcyte's focus on this area could lead to a valuable addition to its product portfolio.
• Commercialization of VAX-PG: VAX-PG, targeting the keystone pathogen responsible for periodontitis, represents a novel approach to addressing a widespread oral health issue. Periodontitis affects a significant portion of the adult population, creating a large potential market for a preventative vaccine. Successful development and commercialization of VAX-PG could establish Vaxcyte in a new therapeutic area.
• Strategic Partnerships: Vaxcyte can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its vaccine candidates. Collaborations can provide access to additional resources, expertise, and distribution networks, enhancing the company's ability to bring its products to market and maximize their impact.

What Opportunities Does PCVX Have?

• Expansion of vaccine pipeline through new targets.
• Strategic partnerships with larger pharmaceutical companies.
• Growing demand for preventative healthcare solutions.
• Addressing the increasing threat of antibiotic resistance.

What Are PCVX's Competitive Advantages?

• Proprietary vaccine technology platform.
• Strong intellectual property portfolio.
• Clinical trial data demonstrating efficacy.
• Experienced management team with expertise in vaccine development.

What Does PCVX Do?

Vaxcyte, Inc., formerly known as SutroVax, Inc., was founded in 2013 and is headquartered in San Carlos, California. The company is dedicated to the development of innovative protein vaccines designed to prevent and treat bacterial infectious diseases. Vaxcyte's core technology focuses on creating vaccines that offer broad protection against prevalent and emerging bacterial strains. Their lead vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials. This vaccine aims to provide comprehensive coverage against the 24 serotypes of Streptococcus pneumoniae, which are responsible for a significant portion of invasive pneumococcal disease and pneumonia cases. Beyond VAX-24, Vaxcyte is also developing VAX-XP, a vaccine designed to protect against emerging pneumococcal strains and address the growing issue of antibiotic resistance. The company's pipeline includes VAX-A1, a conjugate vaccine candidate targeting Group A Streptococcus (GAS), a bacterium responsible for various infections, including strep throat and rheumatic fever. Additionally, Vaxcyte is developing VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis, a common and serious gum infection. Vaxcyte's strategic focus on addressing unmet needs in infectious disease prevention positions it as a key player in the biotechnology sector.

What Products and Services Does PCVX Offer?

• Develop novel protein vaccines to prevent bacterial infectious diseases.
• Focus on vaccines that offer broad protection against prevalent and emerging bacterial strains.
• Conduct clinical trials to evaluate the safety and efficacy of their vaccine candidates.
• Target unmet needs in infectious disease prevention.
• Address the growing issue of antibiotic resistance through innovative vaccine design.
• Develop conjugate vaccines targeting specific bacterial pathogens.

How Does PCVX Make Money?

• Research and development of novel protein vaccines.
• Conducting clinical trials to demonstrate safety and efficacy.
• Seeking regulatory approval from agencies like the FDA.
• Commercializing approved vaccines through partnerships or direct sales.

What Industry Does PCVX Operate In?

Vaxcyte operates within the biotechnology industry, specifically focusing on vaccine development. The global vaccine market is experiencing substantial growth, driven by increasing awareness of preventative healthcare, rising prevalence of infectious diseases, and advancements in vaccine technologies. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing vaccines for various diseases. Vaxcyte differentiates itself through its novel protein vaccine technology and its focus on addressing unmet needs in bacterial infectious diseases. The company's success depends on its ability to navigate the complex regulatory environment and effectively commercialize its vaccine candidates.

Who Are PCVX's Key Customers?

• Healthcare providers (doctors, hospitals, clinics).
• Public health organizations (government agencies).
• Individuals seeking preventative healthcare.
• Pharmacies and distributors.

Vaxcyte, Inc. Financial Trajectory

Vaxcyte, Inc. (PCVX) reported $0 in revenue for Q2 FY2026, based on the latest filing compared to the prior quarter. The company recorded a net loss of $284.3M, with diluted EPS of $-1.97. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, PCVX averaged $-1.91 in diluted EPS.

Company Profile

Vaxcyte, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Carlos, US. The company is led by CEO Grant E. Pickering. PCVX has traded publicly since 2020.

How Vaxcyte, Inc. Is Valued

Vaxcyte, Inc. carries a market capitalization of $8.48B, placing it in the mid-cap category. Analyst price targets span from $58.00 to $163.00, with a consensus of $105.57. At the current price of $58.72, that implies approximately 80% upside potential. Relative to its peer group, PCVX's quantitative score of 54/100 is below the peer average of 70/100.

Return on equity for Vaxcyte, Inc. stands at -32.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -28.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.49 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -13.7%, the inverse of the P/E and a quick read on earnings relative to price.

Vaxcyte, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 11.55 places it in the safe zone, indicating low near-term bankruptcy risk.

Vaxcyte, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 5.0% below estimates on average.

Over the past six months, Vaxcyte, Inc. insiders filed 96 SEC Form 4 transactions — 66 sales and 30 purchases. On net that is roughly 114K shares acquired (about $2.1M) — insiders putting money in tends to read as conviction.

PCVX Financials

PCVX Latest News

PCVX Analyst Consensus

PCVX MoonshotScore

Latest Vaxcyte, Inc. Analysis

Vaxcyte, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources